Pharmaceutical Industry Report - Clinical Report, Drug R&D Report, Pharmaceutical Information

WCLC 2026 Plenary Studies Clinical Evidence Review Report

This report frames the IASLC World Conference on Lung Cancer (WCLC 2026), held 12–15 September 2026 in Seoul, Republic of Korea, around four plenary themes (PL01–PL04) and a dedicated artificial-intelligence-in-oncology track. It provides an integrated clinical-evidence review of nine plenary-anchored studies spanning screening, access and survivorship; small cell lung cancer (SCLC) post-induction strategy and relapsed-SCLC antibody–drug conjugates (ADCs); first-line PD-L1-high and EGFR-driven non-small cell lung cancer (NSCLC); and a mixed EGFR exon 20 insertion / ROS1 / HER2 group. The report is organized around evidence maturity, so each study's clinical question, design, population, treatment versus comparator, endpoints, disclosed findings, and unresolved questions are assessed on the same footing. It clearly separates established readouts (ADAURA's long-term follow-up, PAPILLON's PFS benefit with a pending OS analysis) from interim or topline-only disclosures (REZILIENT3, DESTINY-Lung04), and treats the negative EVOKE-03/KEYNOTE-D46 result — and its subsequent programme discontinuation by Merck and Gilead — as an important interpretive anchor rather than a footnote. It also carefully distinguishes commonly conflated assets and definitions, including Tam-Peli/YL201 as a B7-H3 ADC (not a TROP2 ADC and not risvutatug rezetecan) and ARROS-1's “TKI-naive” cohort of zidesamtinib-treated ROS1-positive patients (not necessarily treatment-naive overall). Aimed at thoracic oncologists, clinical researchers, and medical affairs and market-access teams, the report offers a decision-oriented reference that helps readers rapidly locate where genuinely new information is expected at WCLC 2026, where already-known interim signals are maturing, and where cautious interpretation and independent verification remain essential.

Read →

ESC Congress 2026 Clinical Evidence Review: Seven Pivotal Trials, Guideline Updates, and AI Findings

This report distills the late-breaking and hot-line evidence from the European Society of Cardiology Congress held in Munich, 28–31 August 2026. It provides a side-by-side analysis of seven pivotal trials — CARDIO-TTRansform, ACACIA-HCM, LIBREXIA-ACS, SINGLE-AF, STAREE, PRESC1SE-MI, and CMR GUIDE — spanning ATTR cardiomyopathy, nonobstructive HCM, post-ACS antithrombotic therapy, atrial fibrillation stroke prevention, primary prevention in older adults, ED triage of suspected MI, and ICD-based primary prevention in intermediate-LVEF populations. Built around the underlying numbers, the report presents every trial's sample size, intervention, follow-up, primary endpoint effect estimate (HR/RR/OR with 95% CI and P value), and serious adverse-event profile. A benefit–risk classification grid, safety-signal visualizations, and five interpretive caveats — including the aficamten LVEF-reduction signal, the hypothesis-generating nature of the CARDIO-TTRansform subgroup finding, and the divergence between STAREE's two co-primary endpoints — help readers gauge evidence strength without being misled by isolated P values. Aimed at cardiologists, clinical researchers, and medical affairs and market-access teams, the report closes by clearly separating findings that are clinically actionable now (ACACIA-HCM, SINGLE-AF, STAREE cardiovascular endpoint, PRESC1SE-MI safety) from those that remain hypothesis-generating or non-confirmatory (CARDIO-TTRansform subgroup, LIBREXIA-ACS, CMR GUIDE). A high-density, decision-oriented reference to the strongest cardiovascular evidence out of ESC 2026.

Read →

Oligonucleotide Therapeutics Report: What Patent Intelligence Reveals About the Next Wave of Platform Competition

As oligonucleotides move beyond rare disease into common indications, two forces are deciding who wins: platform IP across chemistry, delivery, and the 2027-2036 expiry wave, and market execution across trials, sponsors, and licensing. - Patent Intelligence: who owns the freedom to operate, and where the platform race is headed next. Oligonucleotide therapeutics are entering a new phase of platform competition, not decided by who owns a therapeutic sequence but by who controls the technology around it. As the field moves beyond early rare-disease proof points into common indications with larger end markets, the centre of value is shifting toward the broader stack: chemical modification, conjugation, delivery, manufacturing, target-tissue access, and platform scalability. This shift raises the bar for Intellectual Property (IP) intelligence. Keyword-based patent search is no longer enough because the signal that matters has moved away from the sequence and into the technology around it (chemical modifications, delivery and conjugation disclosures, and process claims), and increasingly into who is emerging as a platform owner. Reading the landscape now means connecting patent, biological, chemical, clinical, and commercial intelligence in one view. This report uses Patsnap Analytics, Bio, and Synapse to examine how oligonucleotide IP is evolving across four strategic questions: • Who owns the core patent estate across approved products, clinical candidates, and enabling platforms? • How are companies protecting platform value through sequence, formulation, new-use, delivery, conjugation, process, and lifecycle claims? • Where is innovation concentrating across chemistry, delivery, manufacturing, geography, and data assets? • What does the 2027–2036 expiry wave unlock for incumbents, fast-followers, and new platform entrants?

Read →

Oligonucleotide Therapeutics Report: What Clinical and Commercial Intelligence Reveals About the Next Phase of Market Competition

As oligonucleotides move beyond rare disease into common indications, two forces are deciding who wins: platform IP across chemistry, delivery, and the 2027-2036 expiry wave, and market execution across trials, sponsors, and licensing. - Clinical & Commercial Intelligence: who's leading the pipeline, and who's positioned to win in the clinic. Oligonucleotide therapeutics are no longer a niche rare-disease segment. With 25 approved drugs, clinical development is expanding across ASO, siRNA, CRISPR, and aptamer modalities. There is increased focus on extrahepatic delivery, reduced off-target effects, and the sponsor-collaborator model as levers for commercial differentiation. This report utilises Patsnap Synapse to examine the field through a clinical, competitive-intelligence, and BD/licensing lens, connecting approved drugs, clinical trials, sponsors, therapeutic areas, targets, geographic activity, and deal signals. The analysis shows a field entering clinical and commercial maturity, albeit unevenly across platform technologies. ASO remains the front runner whilst siRNA is catching up fast, thanks to validated liver-directed GalNAc delivery. Meanwhile, CRISPR remains predominantly early-stage by trial volume but reached an important maturity inflection in 2026 with the first positive Phase III readout for an in-vivo gene-editing candidate (lonvoguran ziclumeran), and aptamers activities remain focused on ophthalmology. The deal landscape mirrors the clinical pipeline and the maturity stage of the different technology platforms, with capital flowing toward validated assets, delivery technologies, tissue-access platforms, and modality-specific capabilities. China is also becoming an important signal source across clinical activity, sponsor formation, manufacturing capability, and early-stage partnering. The key takeaway is clear: although the modality is programmable, the market will reward selectivity, choosing where target biology, tissue delivery, indication, development path, manufacturing feasibility, and commercial value align. For clinical, BD/licensing, and CI teams, the priority is early signal detection, identifying the next meaningful asset, partner, platform, or competitive shift before it becomes obvious in the market. With fierce competition and new entrants, this report serves to provide insights on • Research activities and whitespace: from targets to indications, what are drug developers focusing on? • Clinical and deal signals based on modalities • Recent partnerships and collaborations - how you can adapt your alliance strategy globally

Read →

2026 BIO International Convention In-Depth Analysis Report

The 2026 BIO International Convention, held June 22-25, 2026 at the San Diego Convention Center, marked a pivotal moment for the biotechnology industry. With nearly 20,000 attendees from over 76 countries (43% international), the event showcased a resurgent biotech sector characterized by record-breaking deal activity, accelerated AI adoption, and renewed investor confidence. The convention's theme, "Driven by Purpose," underscored the industry's commitment to transforming scientific breakthroughs into life-changing therapies. Notable highlights included a landmark $2.5 billion AI-powered drug discovery collaboration, over $100 billion in M&A activity, approximately 70,000 partnering meetings, and transformative regulatory updates from the FDA and EMA.

Read →

EHA 2026 | ATG vs PTCY GVHD Prophylaxis Clinical Outcome Analysis Report

Abstract: EHA-7202 Short: LB5009 The question of whether post-transplant cyclophosphamide (PTCy) should replace anti-thymocyte globulin (ATG/ATLG) as the standard GVHD prophylaxis backbone in HLA-compatible 10/10 matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) has now been directly addressed by a large, prospective randomized controlled trial presented at EHA 2026 by Prof. Johannes Schetelig (Dresden, Germany) and co-investigators including Matthias Stelljes. The trial — designated the GRAPPA study — concludes that ATG-based prophylaxis retains its standard-of-care position in this specific setting, with PTCy failing to demonstrate superiority on the primary composite endpoint. This finding is contextualized against a backdrop of registry data, meta-analyses, and prior Phase 2/3 evidence that had generated significant debate about PTCy's potential to displace ATG in the 10/10 MUD context.

Read →

EHA 2026 | BRUIN CLL-322: Clinical Outcome Analysis Report

Abstract: EHA-7224 Short: LB5001 BRUIN CLL-322 (NCT04965493) is the first randomized Phase 3 trial to evaluate a non-covalent BTK inhibitor–based triplet regimen in previously treated CLL/SLL. With a data cutoff of February 2, 2026, and results presented at EHA 2026, the trial demonstrated that fixed-duration pirtobrutinib + venetoclax–rituximab (PVR) significantly improved progression-free survival over venetoclax–rituximab (VenR) alone, meeting its primary endpoint across all key subgroups. Overall survival data were not yet mature but trended in favor of PVR. This represents Lilly's fourth Phase 3 CLL win for pirtobrutinib (Jaypirca®) and positions PVR as a potential new standard of care in the relapsed/refractory setting.

Read →

EHA 2026 | Gilteritinib vs Midostaurin FLT3 AML Clinical Outcome Analysis Report

Abstract: EHA-7247 Short: LB5005 The PASHA trial is the first randomized Phase 3 head-to-head comparison of a second-generation FLT3 inhibitor (gilteritinib) against the established first-generation standard (midostaurin), both combined with intensive induction/consolidation chemotherapy and followed by one-year maintenance, in patients with newly diagnosed FLT3-mutated AML eligible for intensive therapy. Results were presented as a Late-Breaking Abstract at EHA 2026 (Stockholm, June 2026) by Dr. Marc Raaijmakers on behalf of the HOVON-AMLSG consortium.

Read →

EHA 2026 | SUCCESSOR-2 Phase 3 Readout: MeziKd Demonstrates Clinical Outcome Profile versus Kd in RRMM

Abstract: EHA-7170 Short: LB5004 The Phase 3 SUCCESSOR-2 trial (NCT05552976) demonstrated that adding mezigdomide (a next-generation CELMoD/molecular glue degrader) to the established carfilzomib + dexamethasone (Kd) backbone produced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (RRMM). The trial met its primary endpoint, with MeziKd showing superior PFS and higher response rates versus Kd alone. The overall evaluation was Positive, representing a landmark Phase 3 validation of the CELMoD drug class in combination with a proteasome inhibitor.

Read →